Table 1.
Relative Duration of Influenza Symptoms and Viral Shedding During Oseltamivir Treatment in Hong Kong (2008–2013)a
| Oseltamivir Therapy | All Symptoms |
Feverb |
Respiratory Symptomsc |
Viral Sheddingd |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients, No. | AF (95% CI) | P Value | Patients, No. | AF (95% CI) | P Value | Patients, No. | AF (95% CI) | P Value | Patients, No. | AF (95% CI) | P Value | |
| Started <1 d after illness onset | 36 | 0.44 (.33–.59) | <.01 | 33 | 0.53 (.45–.63) | <.01 | 36 | 0.44 (.33–.59) | <.01 | 37 | 0.83 (.67–1.04) | .11 |
| Started 1–2 d after illness onset | 129 | 0.83 (.66–1.03) | .09 | 114 | 1.06 (.96–1.17) | .23 | 128 | 0.88 (.70–1.11) | .28 | 130 | 1.06 (.92–1.22) | .42 |
| Started >2 d after illness onset | 54 | 0.84 (.61–1.16) | .29 | 40 | 1.08 (.92–1.27) | .32 | 54 | 0.88 (.63–1.23) | .45 | 54 | 0.96 (.78–1.17) | .66 |
| No antiviral | 360 | 1.00 | 287 | 1.00 | 356 | 1.00 | 361 | 1.00 | ||||
Abbreviations: AF, acceleration factor; CI, confidence interval.
a All models were adjusted for index patient characteristics, including age; sex; influenza vaccination in the past year; number of symptoms at baseline; influenza type; presence of any chronic conditions; use of antibiotics, antipyretics, or antihistamines; and study year.
b Not all index patients had fever or respiratory symptoms at baseline.
c Respiratory symptoms included sore throat, cough, coryza, and phlegm.
d Estimated time to cessation of viral shedding by oseltamivir exposure groups, allowing for interval censoring.